hypertension treatment saves 100000
the lance have just published a paper suggesting that improved treatment of blood pressure in England between 1994 and 2011 has saved 100 000 events (myocardial infarcts , strokes and deaths) with 37% of people having good blood pressure control versus 11% at the beginning of the study period. This period overlaps with the National Service framework for coronary disease . Do these changes result from better heart health generally or is this hypertension specific?
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60688-7/abstract (Source: Doc2Doc BMJ Cardiology)
Source: Doc2Doc BMJ Cardiology - May 30, 2014 Category: Cardiology Authors: sadian Source Type: forums
Would you prescribe the polypill?
A systematic review by the Cochrane Collaboration has said that inconsistencies in the design of studies of the polypill make the impact of the drugs difficult to provide. The review showed that polypills have yet to show that they reduce mortality or heart attack and stroke, but they do reduce risk markers, such as stroke and cholesterol.
Another study has found that a single pill can increase adherence to drug regimes by up to 33%.
Doc2doc has debated the polypill before but does the latest study change your thinking in anyway?
Previous doc2doc debates: http://bit.ly/1khiPXG http://bit.ly/1lsLufa
(So...
Source: Doc2Doc BMJ Cardiology - April 29, 2014 Category: Cardiology Authors: AnneG Source Type: forums
Sixth form Idealised four stroke petrol engine
Forum: Chemistry
Posted By: Zenarthra
Post Time: 28-03-2014 at 04:16 (Source: The Student Room)
Source: The Student Room - March 28, 2014 Category: Universities & Medical Training Source Type: forums
Undergraduate Constant stroke volume (LV and RV)
Forum: Biology, biochemistry and other life sciences
Posted By: jsmith6131
Post Time: 22-01-2014 at 01:47 (Source: The Student Room)
Source: The Student Room - January 22, 2014 Category: Universities & Medical Training Source Type: forums
doc2doc podcast: Cardiovascular Team of the Year BMJ Awards 2013
Hi everyone
Just managed to get the embed function fixed on doc2doc and have uploaded a podcast I did a couple of months ago with Professor Lip who was part of the team who won Cardiovascular Team of the Year at the BMJ Awards in 2013. He talked to me about the HasBled risk score which helps assess stroke and bleeding risk for patients with Atrial Fibrillation.
(Source: Doc2Doc BMJ Cardiology)
Source: Doc2Doc BMJ Cardiology - January 2, 2014 Category: Cardiology Authors: mbillingsley Source Type: forums
Post-op AF and anticoagulation
We frequently come across cases of post-op AF, where the stroke risk assessment renders the patient candidate for long term anticoagulation. Would you start anticoagulation in these patients or just treat them with beta-blockers and follow them up in primary care? Many thanks (Source: Doc2Doc BMJ Cardiology)
Source: Doc2Doc BMJ Cardiology - December 19, 2013 Category: Cardiology Authors: DrDi Source Type: forums
What would you like to ask the BMJ Cardiovascular Team of the Year?
For the new doc2doc BMJ Guide to Cardiology, we are interviewing the BMJ Cardiovascular Team of The Year. What questions would you like me to ask them? Please submit your questions below...
Cardiovascular Team of the Year
The Birmingham Atrial Fibrillation Team
University of Birmingham Centre for Cardiovascular Sciences and Sandwell and West Birmingham Hospitals NHS Trust, West Midlands
The team developed a new bleeding risk score specifically for use in Atrial Fibrillation. HAS-BLED provides clinicians with a validated tool to assess bleeding risk, allowing them to identify modifiable ble...
Source: Doc2Doc BMJ Cardiology - October 18, 2013 Category: Cardiology Authors: Matthew Billingsley Source Type: forums
ALTITUDE Autopsy Shows What Went Wrong With Aliskiren
In its short lifespan the direct renin inhibitor aliskiren (a.k.a., Rasilez or Tekturna) rapidly declined from being a highly promising, first-of-its kind drug to a major failure. The death blow was struck last December with the early termination of the ALTITUDE trial, after the data and safety monitoring committee found an increased risk in patients taking aliskiren. Now the final results of the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints have been presented at Kidney Week 2012 in San Diego and simultaneously published in the New England Journal of Medicine.
8,561 type 2 diabetics at high risk f...
Source: CardiologyNetwork.com - October 13, 2013 Category: Cardiology Authors: Indian Diabetics Foundation Team Source Type: forums
Rivaroxaban Gains FDA Indications for Treating and Preventing DVT and PE
The FDA has expanded the indication for rivaroxaban (Xarelto, Johnson & Johnson) to include the treatment of deep-vein thrombosis (DVT) and pulmonary embolism (PE) and to reduce the risk for recurrent DVT and PE.
The oral anticoagulant is already approved to reduce postsurgical risk for DVT and PE after hip- and knee-replacement surgery and to reduce the risk for stroke in people with atrial fibrillation. The new indication was granted under the FDA’s priority review program.
“Xarelto is the first oral anti-clotting drug approved to treat and reduce the recurrence of blood clots since the approval of warfarin nea...
Source: CardiologyNetwork.com - October 13, 2013 Category: Cardiology Authors: Indian Diabetics Foundation Team Source Type: forums
Ablation for Treatment-Naive A-Fib Patients?
In this study, Danish researchers randomized 294 treatment-naive patients with paroxysmal atrial fibrillation to receive either radiofrequency catheter ablation or standard therapy with class IC or class III antiarrythmic drugs. At 2 years, the burden of a-fib was significantly lower in those receiving ablation than in those receiving antiarrythmic drug therapy (90th percentile, 9% vs. 18%; P=0.007). Three patients in the ablation group had cardiac tamponade related to the procedure. One patient in the ablation group died from a procedure-related stroke. About a third of the patients in the drug treatment group underwent s...
Source: CardiologyNetwork.com - October 13, 2013 Category: Cardiology Authors: Indian Diabetics Foundation Team Source Type: forums
Do you consider smoking status when prescribing clopidogrel?
Clopidogrel was a massive earner for its manufacturer while its patent lasted, but like so many drugs which have cost health systems billions in long-term treatment, it may not actually do that much for most people who take it. A meta-analysis of nine trials in patients with established cardiovascular disease, the effect of clopidogrel was highly dependent on smoking status. Those who smoked showed a 25% reduction in a composite outcome of cardiovascular death, myocardial infarction or stroke, compared with a reduction of 8% in non-smokers. This may also apply to the newer agents ticagrelor and prasugrel, though ...
Source: Doc2Doc BMJ Cardiology - October 7, 2013 Category: Cardiology Authors: Richard Lehman Source Type: forums
Help: How can left-sided hypertrophy coexist with hypertension?
Can someone explain how a patient can have left-sided hypertrophy of the heart along with hypertension?
I thought: left ventricular hypertrophy --> reduced ventricular filling --> reduced stroke volume --> reduced cardiac output --> decreased blood pressure --> no hypertension.
In some of the cases I read, they don't mention heart rate or peripheral resistance, yet they say the patient has left ventricular hypertrophy and hypertension. So, do I have to assume that the heart rate and peripheral resistance are high for that patient? Even if heart rate and peripheral resistance are high, if the ven...
Source: Student Doctor Network Forums - September 8, 2013 Category: Universities & Medical Training Authors: pizza100 Tags: Allopathic Source Type: forums
Is Des Spence right about AF? Is AF case finding and anticoagulation bad medicine?
I often read Des Spence's piece in the print journal and last week he wrote about AF. http://www.bmj.com/content/347/bmj.f4910His argument is that AF case finding and anticoagulation is bad medicine. Mine is that in an average patient on a GP list the stroke risk per year is is 0 or close to because of the demographics and the way that the statistics of risk play out ( a high risk patient with AF has a stroke risk of about 5% per year). In the same edition there is news piece saying that reconfiguration of stroke care in London has saved lives and money - don't we need a public health perspe...
Source: Doc2Doc BMJ Cardiology - August 13, 2013 Category: Cardiology Authors: sadian Source Type: forums
Is Des Spence right about AF?
I often read Des Spence's piece in the print journal and last week he wrote about AF. http://www.bmj.com/content/347/bmj.f4910His argument is that AF case finding and anticoagulation is bad medicine. Mine is that in an average patient on a GP list the stroke risk per year is is 0 or close to because of the demographics and the way that the statistics of risk play out ( a high risk patient with AF has a stroke risk of about 5% per year). In the same edition there is news piece saying that reconfiguration of stroke care in London has saved lives and money - don't we need a public health perspective...
Source: Doc2Doc BMJ Cardiology - August 13, 2013 Category: Cardiology Authors: sadian Source Type: forums
